Ultra-small nanomedicines which stably deliver oligonucleotides to refractory cancers

(Innovation Center of NanoMedicine) Ultra-small nanomedicines with a size of ca. 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and oligonucleotide drugs. Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the bloodstream. The size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues. Clinical trials and preclinical studies using the developed ultra-small nanomedicines are proceeding for refractory cancer therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news